

23 April 2026

BPH Global Ltd Advances BRIN Collaboration to Stage 2 Development of Seaweed-based anti-aging supplement

Highlights

- BPH Global's Indonesian subsidiary, PT BPH Global Indonesia, has entered Stage 2 of its collaboration with Indonesia's National Research and Innovation Agency (BRIN)
- Stage 2 has been formalised through execution of:
 - (i) a Cooperation Agreement (Perjanjian Kerja Sama); and
 - (ii) a detailed Terms of Reference (Kerangka Acuan Kerja).
- This follows the execution of a binding Memorandum of Understanding (MoU) with BRIN announced on 6 February 2026.
- The agreements represent the first project-specific implementation under the MoU.
- Stage 2 focuses on development of fucoidan extraction technology and a fucoidan-based powdered supplement prototype for food and beverage applications.
- BRIN anticipates delivery of a prototype within approximately three (3) months from commencement.
- Defined financial contributions have been agreed between the parties for Stage 2.
- Successful completion of the prototype phase is expected to inform progression to Stage 3 commercialisation.

The Board of BPH Global Ltd (**ASX: BP8**) (**BP8, BPH Global or Company**) a leading commercial seaweed supply and export Company, is pleased to advise that its Indonesian operating subsidiary, PT BPH Global Indonesia, has executed a binding Cooperation Agreement and accompanying Terms of Reference with Badan Riset dan Inovasi Nasional (BRIN), Indonesia's National Research and Innovation Agency.

This follows the execution of a binding Memorandum of Understanding (MoU) between the parties, as announced on [6 February 2026](#), and marks the transition from **Stage 1 (framework collaboration)** to **Stage 2 (project execution)** under BRIN's structured innovation model.

Stage 2 – Project Scope

The Stage 2 agreements govern the first collaborative R&D project between the parties, focused on fucoidan extraction technology and downstream product development.

The project includes:

- Joint research and technical development
- Raw material characterisation
- Scale-up of extraction processes to a 10kg input level
- Quality standardisation
- Development of a fucoidan-based powdered supplement prototype for use as a food and beverage additive

Outputs are expected to include:

- A fucoidan extract prototype and specifications.
- A draft intellectual property outcome.
- Development of fucoidan as a nutraceutical raw material.

Funding and Financial Commitments

The Stage 2 project will be funded through a combination of direct expenditure by BPH Global and in-kind contributions from BRIN as follows:

- **BPH Global contribution (cash-funded components):** approximately IDR 145.9 million (~A\$14,600), comprising:
 - Raw seaweed materials
 - Labour and technical support
 - Chemicals and processing inputs
 - Supporting materials
 - Rental of production equipment (including extraction and drying systems)
- **BRIN contribution (in-kind):** approximately IDR 62.0 million (~A\$6,200), comprising:
 - Laboratory testing and analytical services (including FTIR, GPC, UV-Vis and related analysis)

Total project value is approximately IDR 207.9 million (~A\$20,800). Each party will bear its respective costs in accordance with the Cooperation Agreement.

Fucoidan Technology and Strategic Context

Fucoidan is a bioactive compound derived from brown seaweed and is widely utilised globally in functional food, nutraceutical and cosmetic applications.

BRIN holds existing, formally registered background intellectual property in Indonesia relating to fucoidan extraction technology, which underpins this collaboration. The project is directed toward establishing domestic Indonesian capability to produce fucoidan as a bulk raw material, supporting downstream industry applications and reducing reliance on imports.

Timeline and Pathway to Commercialisation

Work under the Stage 2 agreements is expected to commence in the coming week, with a prototype targeted within approximately three (3) months.

Upon successful completion of this proof-of-concept phase, the parties intend to:

- Assess technical and commercial viability
- Progress discussions regarding licensing of BRIN technology
- Consider advancement to Stage 3 (commercialisation), expected to be governed by separate commercial agreements

About BRIN

Badan Riset dan Inovasi Nasional (**BRIN**) is Indonesia's National Research and Innovation Agency and a cabinet-level government institution operating under the President of the Republic of Indonesia. BRIN is responsible for coordinating, conducting and promoting research, development, assessment and application of science and technology across Indonesia.

BRIN plays a central role in Indonesia's research down streaming (*hilirisasi*) strategy, which seeks to translate publicly funded research into applied technologies and commercially viable outcomes through structured collaboration with industry across priority sectors including marine bioindustry, advanced materials, agriculture and strategic manufacturing.

– ENDS –

Authorised for release by:
The Board of BPH Global Ltd

For further information, please visit our website at www.bphglobal.com or contact the Company Secretary on 03 9088 2049.